Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function

Pharmacology

Volumn 81, Issue 2, 2008, Pages 118-126

  Tamura, Tadafumi ^a   Matsubara, Masahiro ^a   Amano, Toru ^a   Chida, Michihiro ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Animal model; Antihistamine; Olopatadine hydrochloride; Scratching behavior; Skin barrier

Indexed keywords

BETAMETHASONE; CYTOKINE; GAMMA INTERFERON; HYALURONIC ACID; INTERLEUKIN 4; MESSENGER RNA; NERVE GROWTH FACTOR; OLOPATADINE; OXAZOLONE; PROTEIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DERMATITIS; DRUG EFFICACY; EAR; FIBROBLAST; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SKIN; SKIN INFLAMMATION; SKIN WATER LOSS; SPRAGUE DAWLEY RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; CYTOKINES; DERMATITIS; DIBENZOXEPINS; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SKIN; WATER LOSS, INSENSIBLE;

EID: 38749146486     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110112     Document Type: Article

References (32)

1. Wahlgren CF: Itch and atopic dermatitis: an overview. J Dermatol 1999;26:770-779.
2. Nakamura M, Toyoda M, Morohashi M: Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 2003;149:718-730.
3. Stander S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T: Neurophysiology of pruritus: cutaneous elicitation of itch. Arch Dermatol 2003;139:1463-1470.
4. Lodén M, Andersson AC, Lindberg M: Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm®). Br J Dermatol 1999;140:264-267.
5. Rim JH, Jo SJ, Park JY, Park BD, Youn JI: Electrical measurement of moisturizing effect on skin hydration and barrier function in psoriasis patients. Clin Exp Dermatol 2005;30:409-413.
6. Kobayashi H, Kikuchi K, Tsubono Y, Tagami H: Measurement of electrical current perception threshold of sensory nerves for pruritus in atopic dermatitis patients and normal individuals with various degrees of mild damage to the stratum corneum. Dermatology 2003;206:204-211.
7. Maytin EV, Chung HH, Seetharaman VM: Hyaluronan participates in the epidermal response to disruption of the permeability barrier in vivo. Am J Pathol 2004;165:1331-1341.
8. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA: New insights into atopic dermatitis. J Clin Invest 2004;113:651-657.
9. Kitagaki H, Ono N, Hayakawa K, Kitazawa T, Watanabe K, Shiohara T: Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T-helper cell type 1 to a T-helper cell type 2 profile. J Immunol 1997;159:2484-2491.
10. Tamura T, Matsubara M, Takada C, Hasegawa K, Suzuki K, Ohmori K, Karasawa A: Effects of olopatadine hydrochloride, an antihistamine drug, on skin inflammation induced by repeated topical application of oxazolone in mice. Br J Dermatol 2004;151:1133-1142.
11. Tamura T, Amano T, Ohmori K, Manabe H: The effects of olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice. Eur J Pharmacol 2005;524:149-154.
12. Fujii Y, Takeuchi H, Tanaka K, Sakuma S, Ohkubo Y, Mutoh S: Effects of FK506 (tacrolimus hydrate) on chronic oxazolone-induced dermatitis in rats. Eur J Pharmacol 2002;456:115-121.
13. Craven NM, Jackson CW, Kirby B, Perrey C, Pravica V, Hutchinson IV, Griffiths CE: Cytokine gene polymorphisms in psoriasis. Br J Dermatol 2001;144:849-853.
14. Spergel JM, Mizoguchi E, Oettgen H, Bhan AK, Geha RS: J Clin Invest 1999;103:1103-1111.
15. 2+-dependent protein kinase C, Raf/MEK/ERK and IKK/IκB/NF-κB signal cascades. Biochem Pharmacol 2005;69:433-449.
16. Izu K, Tokura Y: The various effects of four H1-antagonists on serum substance P levels in patients with atopic dermatitis. J Dermatol 2005;32:776-781.
17. Bull HA, Leslie TA, Chopra S, Dowd PM: Expression of nerve growth factor receptors in cutaneous inflammation. Br J Dermatol 1998;139:776-783.
18. Pincelli C, Marconi A: Autocrine nerve growth factor in human keratinocytes. J Dermatol Sci 2000;22:71-79.
19. Kinkelin I, Motzing S, Koltenzenburg M, Brocker EB: Increase in NGF content and nerve fiber sprouting in human allergic contact eczema. Cell Tissue Res 2000;302:31-37.
20. Dou YC, Hagstromer L, Emtestam L, Johansson O: Increased nerve growth factor and its receptors in atopic dermatitis: an immunohistochemical study. Arch Dermatol Res 2006;298:31-37.
21. Toyoda M, Nakamura M, Makino T, Morohashi M: Localization and content of nerve growth factor in peripheral blood eosinophils of atopic dermatitis patients. Clin Exp Allergy 2003;33:950-955.
22. Kanda N, Watanabe S: Histamine enhances the production of nerve growth factor in human keratinocytes. J Invest Dermatol 2003;121:570-577.
23. 1 receptor-deficient mice (in Japanese). Jpn J Allergol 2003;52:477P.
24. Wood LC, Jackson SM, Elias PM, Grunfeld C, Feingold KR: Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J Clin Invest 1992;90:482-487.
25. Nickoloff BJ, Naidu Y: Perturbation of skin barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol 1994;30:535-536.
26. 1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology 2005;75:45-52.
27. Lee CH, Chuang HY, Shih CC, Jong SB, Chang CH, Yu HS: Transepidermal water loss, serum IgE and β-endorphin as important and independent biological markers for development of itch intensity in atopic dermatitis. Br J Dermatol 2006;154:1100-1107.
28. Belloni G, Pinelli S, Veraldi S: A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair) in the treatment of mild to moderate atopic dermatitis. Eur J Dermatol 2005;15:31-36.
29. Kao JS, Fluhr JW, Man MQ, Fowler AJ, Hachem JP, Crumrine D, Ahn SK, Brown BE, Elias PM, Feingold KR: Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003;120:456-464.
30. Ahn SK, Bak HN, Park BD, Kim YH, Youm JK, Choi EH, Hong SP, Lee SH: Effects of a multilamellar emulsion on glucocorticoid-induced epidermal atrophy and barrier impairment. J Dermatol 2006;33:80-90.
31. Fukaya M: Improvement of atopic dermatitis after discontinuation of topical corticosteroid treatment. Arch Dermatol 2000;136:679-680.
32. Tamura T, Matsubara M, Hasegawa K, Ohmori K, Karasawa A: Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity. Clin Exp Allergy 2005;35:97-103.